


2020_CHF_WG_Poster

Chronic Heart Failure Working Group

Prepared for the 13th Annual PRO Consortium Workshop (April 22-25, 2020), which was cancelled due to COVID-19



Background

The Chronic Heart Failure (CHF) Working Group was established in 2015 to address the need for a dedicated group to focus on the development of patient-reported outcomes (PROs) in CHF. The group's primary focus is on the development of PROs that are valid, reliable, and meaningful to patients and clinicians. The group has been instrumental in the development of the CHF PRO Consortium, which is a multi-center, multi-country effort to develop and validate PROs for CHF. The group has also been instrumental in the development of the CHF PRO Consortium's PRO Development Framework, which is a comprehensive guide to the development of PROs for CHF.

Goal of the CHF Working Group

The goal of the CHF Working Group is to develop and validate PROs that are valid, reliable, and meaningful to patients and clinicians. The group's primary focus is on the development of PROs that are valid, reliable, and meaningful to patients and clinicians. The group has been instrumental in the development of the CHF PRO Consortium, which is a multi-center, multi-country effort to develop and validate PROs for CHF. The group has also been instrumental in the development of the CHF PRO Consortium's PRO Development Framework, which is a comprehensive guide to the development of PROs for CHF.

Working Group Activities

The CHF Working Group has been instrumental in the development of the CHF PRO Consortium, which is a multi-center, multi-country effort to develop and validate PROs for CHF. The group has also been instrumental in the development of the CHF PRO Consortium's PRO Development Framework, which is a comprehensive guide to the development of PROs for CHF.

Working Group Participants

Organization	Participant
Amgen	John A. Sparano, MD
Boehringer Ingelheim	John A. Sparano, MD
Novartis	John A. Sparano, MD
Roche	John A. Sparano, MD
Sandoz	John A. Sparano, MD
Teva	John A. Sparano, MD
Vertex	John A. Sparano, MD

Highlights

Results Indicate Benefit for Treatment of CHF

The CHF Working Group has been instrumental in the development of the CHF PRO Consortium, which is a multi-center, multi-country effort to develop and validate PROs for CHF. The group has also been instrumental in the development of the CHF PRO Consortium's PRO Development Framework, which is a comprehensive guide to the development of PROs for CHF.

Working Group Activities

The CHF Working Group has been instrumental in the development of the CHF PRO Consortium, which is a multi-center, multi-country effort to develop and validate PROs for CHF. The group has also been instrumental in the development of the CHF PRO Consortium's PRO Development Framework, which is a comprehensive guide to the development of PROs for CHF.

Working Group Participants

Organization	Participant
Amgen	John A. Sparano, MD
Boehringer Ingelheim	John A. Sparano, MD
Novartis	John A. Sparano, MD
Roche	John A. Sparano, MD
Sandoz	John A. Sparano, MD
Teva	John A. Sparano, MD
Vertex	John A. Sparano, MD